Literature DB >> 26063717

Editorial Commentary: Fosfomycin: The Current Status of the Drug.

Matthew E Falagas1, Petros I Rafailidis2.   

Abstract

Entities:  

Keywords:  Enterobacteriaceae; Escherichia coli; fosfomycin; multidrug-resistant; prostatitis

Mesh：

Substances：

Year:  2015        PMID： 26063717     DOI： 10.1093/cid/civ443

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  5 in total

1.  Efficacy and Safety of Oral Fosfomycin-Trometamol in Male Urinary Tract Infections with Multidrug-Resistant Enterobacterales.

Authors:  Kévin Bouiller; Souheil Zayet; Paul-Emile Lalloz; Anaïs Potron; Vincent Gendrin; Catherine Chirouze; Timothée Klopfenstein
Journal:  Antibiotics (Basel)       Date:  2022-02-03

2.  Long-Term Fosfomycin-Tromethamine Oral Therapy for Difficult-To-Treat Chronic Bacterial Prostatitis.

Authors:  Ibai Los-Arcos; Carles Pigrau; Dolors Rodríguez-Pardo; Nuria Fernández-Hidalgo; Antonia Andreu; Nieves Larrosa; Benito Almirante
Journal:  Antimicrob Agents Chemother       Date:  2015-12-14       Impact factor: 5.191

Review 3.  Oral Fosfomycin for the Treatment of Acute and Chronic Bacterial Prostatitis Caused by Multidrug-Resistant Escherichia coli.

Authors:  George G Zhanel; Michael A Zhanel; James A Karlowsky
Journal:  Can J Infect Dis Med Microbiol       Date:  2018-01-30       Impact factor: 2.471

Review 4.  Pharmacological Interventions for Bacterial Prostatitis.

Authors:  Situ Xiong; Xiaoqiang Liu; Wen Deng; Zhengtao Zhou; Yulei Li; Yechao Tu; Luyao Chen; Gongxian Wang; Bin Fu
Journal:  Front Pharmacol       Date:  2020-04-30       Impact factor: 5.810

Review 5.  Fosfomycin: A First-Line Oral Therapy for Acute Uncomplicated Cystitis.

Authors:  George G Zhanel; Andrew J Walkty; James A Karlowsky
Journal:  Can J Infect Dis Med Microbiol       Date:  2016-05-10       Impact factor: 2.471
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.